Efgartigimod for the Treatment of Guillain-Barré Syndrome

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 13, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Guillain-Barre Syndrome (GBS)

Interventions

DRUG

efgartigimod

efgartigimod 20 mg/kg was administered via intravenous infusion on day 1 and day 5 of the treatment period only.

All Listed Sponsors

lead

Zhongming Qiu

OTHER

NCT06885762 - Efgartigimod for the Treatment of Guillain-Barré Syndrome | Biotech Hunter | Biotech Hunter